Antiviral Drugs as Life-Cycle Interruptions | AI Learning Guide

Think of an antiviral drug as a roadblock placed at one specific point on the life-cycle route. An entry inhibitor stops the virus before it ever gets inside the cell. A polymerase inhibitor stops the copying of the genome once the virus is inside. A protease inhibitor stops the final cutting step that turns a long viral protein chain into working parts. Resistance happens when the virus finds a detour: a mutation that changes the shape of the drug's target just enough that the drug no longer fits, but the viral protein can still do its job. Because RNA viruses make mistakes every time they copy their genome, some resistant viruses already exist before treatment starts, and the drug simply gives them an advantage. That is why doctors combine drugs that block different steps: the virus would need to find several detours at once, which is far less likely.

0:00 / 0:00

Auto-play

Matching drug classes to life-cycle steps

Each class of antiviral drug is defined by the step it interrupts. Entry inhibitors act before the genome reaches the cytoplasm, so they reduce the number of cells that become infected. Polymerase inhibitors act after uncoating, when the genome must be copied, and they reduce the yield of new genomes per infected cell. Protease inhibitors act late, during maturation, and they reduce the infectivity of the particles that are released. The clinical consequence of this timing is that entry inhibitors and polymerase inhibitors reduce the spread of infection within a tissue, while protease inhibitors reduce the number of infectious particles produced by an already infected cell.

Why resistance is predictable

A resistance mutation must satisfy two conditions simultaneously: it must weaken the interaction with the drug, and it must preserve the essential function of the target protein. For an enzyme like a polymerase, the active site is under strong functional constraint, so resistance often arises from mutations at the periphery of the binding pocket that change its shape without disrupting catalysis. For a surface protein like an entry protein, the constraint is different: the protein must still bind the receptor and undergo fusion, so resistance mutations often alter the epitope or the drug-binding surface while leaving the receptor-binding site intact. Because the mutation rate of RNA viruses is high, resistant variants are present in the population even before treatment begins, and the drug selects for them.

Combination therapy

If a single drug selects for one resistance mutation, combining drugs that target different steps or different sites within the same step requires the virus to acquire multiple independent mutations simultaneously. The probability of that event is the product of the individual mutation probabilities, which is why combination therapy is standard for rapidly mutating viruses such as HIV and hepatitis C.